SCHEMBL6538481

SCHEMBL6538481

COC(=O)c1cc(-c2ccc(=O)n(C(C)C)n2)c(-c2ccccc2)nc1OCC(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.39
NTRK1 P04629 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA3 P34903 1/20 0.35
ACACA Q13085 3/20 0.35
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
ATR Q13535 1/20 0.35
CMKLR1 Q99788 1/20 0.34
DPP4 P27487 1/20 0.34
AKT1 P31749 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538824 0.83 MEN1 (0.39) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6538457 0.83 MAPT (0.41) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6538930 0.82 POLB (0.42) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6538316 0.81 TP53 (0.39) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6538650 0.81 MAPT (0.39) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6539144 0.81 ALDH1A1 (0.47) NTRK1MAPTALDH1A1NPSR1ACACA
SCHEMBL6538327 0.80 MAPT (0.38) NTRK1MEN1KMT2AMAPTALDH1A1
SCHEMBL6539265 0.80 MEN1 (0.40) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6538780 0.80 MEN1 (0.37) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL6133415 0.78 ALDH1A1 (0.39) ALDH1A1NPSR1TP53DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 CNR1 533/4885NTRK1 2778/4885MEN1 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.